Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
about
Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical reviewFc glycans of therapeutic antibodies as critical quality attributesApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsTargeting the Fc receptor in autoimmune diseaseCrystal structure of Streptococcus pyogenes EndoS, an immunomodulatory endoglycosidase specific for human IgG antibodiesImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesThe eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disordersIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activityComparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsModern Technologies for Creating Synthetic Antibodies for Clinical application.Systems analysis of N-glycan processing in mammalian cellsDouble knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCCTwo mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Next generation of antibody therapy for cancer.A new look at the pathogenesis of asthmaMolecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.New paradigms for functional HIV-specific nonneutralizing antibodiesPeptide-displaying phage technology in glycobiologyPlant glyco-biotechnology on the way to synthetic biologyA novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus.Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.The characterization and quantitation of glycomic changes in CHO cells during a bioreactor campaign.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.The GalNAc-type O-Glycoproteome of CHO cells characterized by the SimpleCell strategyOverexpression of α1,6-fucosyltransferase in hepatoma enhances expression of Golgi phosphoprotein 2 in a fucosylation-independent manner.Intramolecular N-glycan/polypeptide interactions observed at multiple N-glycan remodeling steps through [(13)C,(15)N]-N-acetylglucosamine labeling of immunoglobulin G1.Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expressionReduction in C-terminal amidated species of recombinant monoclonal antibodies by genetic modification of CHO cells.Chemoenzymatic synthesis and Fcγ receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to FcγIIIa receptor.Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.A common glycan structure on immunoglobulin G for enhancement of effector functionsGeneration and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.Model-based analysis of N-glycosylation in Chinese hamster ovary cells.Targeted genetic modification of cell lines for recombinant protein production.Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases.Post-translational modifications in the context of therapeutic proteins.
P2860
Q26782025-B5B146CD-2357-4C48-B071-D6B8D6AAAD0AQ26799266-8083C890-1C43-4EB2-8CD2-7E3EC2BF3C21Q26852287-64DB4FAC-096F-423F-87BD-87D941D8EBAAQ27002843-345EA64E-F1A0-4E51-940C-93FFBA838735Q27683509-5605D450-8136-48ED-BB46-31ABA7CDB985Q28069362-0626C81F-7997-4FE1-99DD-D574F02A146FQ28307714-C3509F2F-3712-4491-B2DC-F6886FD72FF2Q28547176-014180BF-F208-486D-AE6F-C315AEBAB972Q28820826-69ACE1E0-F3EC-4F95-BF2C-F9E5F64989DEQ30467308-6E2216E5-8127-43E8-B3F2-547046F93D1DQ33293527-1DA8BB77-ECEC-44C2-B9A4-AD8F5A0A6F4DQ33307815-BBAAF042-DEB5-456A-86D6-79AF5FA25E1CQ33410392-AD65102D-0047-4028-AD40-69CAF1816CC6Q33579636-6225AC0A-F0F1-4C62-849A-0D50F24ACF7CQ33588457-862672A9-5D09-4BC0-A32B-D61AC6C12601Q33786180-6866E4FA-3834-4DCA-B306-C422053A5DDCQ33900573-9F3D7A03-30BD-497B-9C32-B089E6059331Q33900595-72BBD03B-F9B7-479D-AAEB-0A121C91FD50Q34022620-D02F72F7-C73E-44EE-AEC4-DEAFE807AF5CQ34304795-13A1FE76-E5B6-454F-89FE-F228E9C3B3D6Q34322432-75146D89-5476-4D86-81A5-3CABA0CEC84DQ34323394-5D55592B-34E2-46D5-82F0-8DAA604911A7Q34323725-27441593-AAF9-4360-85BD-28536280520AQ34574834-4B7182E8-93E4-41D1-9B58-23C645495E98Q34634855-1F6F772D-9C01-450D-85B8-227C3DC17A12Q34984675-23ED284F-B847-489B-B8D1-B33A0841C3AAQ34999126-BEE6DEBD-2AAF-414D-A265-B308947F803AQ35000274-CC5B28FE-D8A5-4540-8C09-AC801ED8AC45Q35225062-564B4B5B-3957-4CD3-A67E-7770A488E8A9Q35555990-1596266D-50A6-45EF-812F-D6AF139EE58CQ35705039-64AE6464-2A30-4CDA-A705-12E2E22AADB7Q36008257-FE2581E5-D220-4322-960C-EC3A5110BCD9Q36015321-478DEB70-5102-4CC4-B835-A40BF13D5CFBQ36023146-025A63FB-2CB8-4237-AFE4-5659DD8121E9Q36131665-7171B7E7-52A2-4951-956E-2FD237A3369CQ36189447-C6679DF1-FF33-4A48-A723-97B50434335DQ36366942-E1BCF0F1-D13F-477C-8E7A-5C7BCFF14B02Q36495991-C1E8A060-B253-4064-8022-B0419258905CQ36545930-61C797D9-7758-4487-A2D6-376A1F51ACEDQ36620451-495780DB-DC02-4EED-BAF0-7AE70BDCF8B4
P2860
Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@ast
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@en
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@nl
type
label
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@ast
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@en
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@nl
prefLabel
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@ast
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@en
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@nl
P2093
P4510
P921
P356
P1476
Establishment of FUT8 knockout ...... pendent cellular cytotoxicity.
@en
P2093
Kazuhisa Uchida
Kenya Shitara
Machi Kusunoki
Masako Wakitani
Miho Inoue-Urakubo
Mikiko Sakurada
Mitsuo Satoh
Naoko Yamane-Ohnuki
Rinpei Niwa
Ryosuke Nakano
P304
P356
10.1002/BIT.20151
P577
2004-09-01T00:00:00Z